The year 2025 has seen a massive restructuring of corporate governance within the biotech industry, with at least 20 companies reporting changes in their chairpersons—the highest density of leadership turnover in history. The shifts are categorized into three main themes: changes in ownership, major shareholders stepping back, and generational succession.
Read more
